Pfizer Gets Abuse-Deterrent Claim on One Pain Drug, Then Drops Development of Another
This article was originally published in RPM Report
Executive Summary
Pfizer got its first abuse-deterrent claim for its pain therapy Embeda. But it has also ended an agreement to develop another potential abuse-deterrent pain drug.
You may also be interested in...
Remoxy Development Not ‘Unmitigated Disaster,’ CEO Reassures; Hunt Begins For New Partner
Pfizer terminates agreement with Pain Therapeutics after reviewing top-line results of five studies done to address FDA complete response letter; Pain says data supports refiling of NDA for its abuse-deterrent long-acting oxycodone formulation by mid-2015.
Getting Organized on Abuse-Deterrent Opioids: FDA Calls For Volunteers Ahead of Oct. 30-31 Meeting
FDA is planning a two-day workshop on issues related to abuse-deterrent opioid formulations, and wants to hear unified presentations from the brand and generic industry. That is easier said than done.
Seeking Guidance On Abuse-Deterrence: Sponsors Fall Short, Congress Urges Action
Congressional appropriators are urging FDA to move quickly to finalize guidance on abuse deterrence claims for opioids—and to take the next step and prohibit marketing of products that don’t deter abuse. FDA says the science isn’t there yet, and two sponsors join the list of those who have failed to clear the hurdle.